Cue Biopharma (NASDAQ:CUE) CEO Shao-Lee Lin Sells 18,258 Shares of Stock

Cue Biopharma, Inc. (NASDAQ:CUE) CEO Shao-Lee Lin sold 18,258 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $28.62, for a total value of $522,543.96. Following the completion of the sale, the chief executive officer directly owned 705,995 shares of the company’s stock, valued at approximately $20,205,576.90. This trade represents a 2.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shao-Lee Lin also recently made the following trade(s):

• On Wednesday, August 12th, Shao-Lee Lin sold 40,000 shares of Cue Biopharma stock. The stock was sold at an average price of $27.10, for a total value of $1,084,000.00.

Cue Biopharma Stock Up 10.0%

CUE opened at $34.20 on Friday. Cue Biopharma, Inc. has a 52 week low of $4.97 and a 52 week high of $45.50. The business’s 50 day moving average is $29.50 and its two-hundred day moving average is $147.28. The firm has a market cap of $143.64 million, a price-to-earnings ratio of -6.12 and a beta of 2.47.

Cue Biopharma (NASDAQ:CUE) last announced its earnings results on Friday, August 14th. The company reported ($24.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.69) by ($22.45). The business had revenue of $7.88 million for the quarter, compared to analysts’ expectations of $3.00 million. Cue Biopharma had a negative return on equity of 98.30% and a negative net margin of 59.65%.

Analyst Ratings Changes

Several research firms have recently commented on CUE. Wall Street Zen cut shares of Cue Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday. Weiss Ratings raised Cue Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, May 18th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Cue Biopharma during the 2nd quarter valued at approximately $83,000. Persistent Asset Partners Ltd acquired a new stake in shares of Cue Biopharma in the 2nd quarter worth approximately $389,000. Texas Capital Bank Wealth Management Services Inc purchased a new position in Cue Biopharma in the 2nd quarter valued at approximately $722,000. ADAR1 Capital Management LLC purchased a new position in Cue Biopharma in the 2nd quarter valued at approximately $1,742,000. Finally, BlackRock Inc. acquired a new position in Cue Biopharma during the second quarter worth $1,824,000. 35.04% of the stock is owned by hedge funds and other institutional investors.

About Cue Biopharma

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.